Guidelines for breast cancer treatment recommend local therapy for patients with symptomatic BM, such as surgical resection or irradiation, and to continue with the same anti-HER2 therapy if the systemic clinical benefit persists3–6. Here, ERBB2 is linked to breast cancer.